Navigation Links
NeurogesX Reports First Quarter 2011 Results
Date:4/29/2011

se initiatives allowed us to moderate planned spending growth and as a result, we have reduced our planned operating expenses for 2011 by approximately 14% from prior guidance.  Our 2011 operating expenses are now expected to be in the range of $50 million to $53 million.  Our primary focus remains on ensuring the continued adoption of Qutenza, recognizing the longer term nature of the investments necessary for success.  Other key activities include submission of a supplemental NDA for Qutenza for the management of neuropathic pain associated with HIV-associated neuropathy (HIV-AN) as well as advancing the clinical development of NGX-1998, our topical liquid formulation containing a high concentration capsaicin.  With our reduced expenses and continued focus on our key operational initiatives, we continue to pursue opportunities to increase our capital."  

Investor DayNeurogesX will host an investor day today from 8:15 am - 11:00 am EDT at The New York Palace Hotel in New York.  As part of the presentation, management will review results for the first quarter ended March 31, 2011.  The Company will provide an update on the US launch of the Qutenza® (capsaicin) 8% patch and on the development of NGX-1998. The Investor Day will be webcast live and archived for 30 days on the investor relations section of the NeurogesX website at www.neurogesx.com.

About NeurogesX, Inc.NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. NeurogesX Receives Notice of Allowance for Patent Covering NGX-1998 Capsaicin Topical Liquid
2. NeurogesX Reports Fourth Quarter and Year-End 2010 Results
3. NeurogesX to Provide Qutenza® Launch Update
4. NeurogesX to Present at Two February Investor Conferences
5. NeurogesX Receives Qutenza®-Specific J-Code From Centers for Medicare and Medicaid Services (CMS)
6. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
7. NeurogesX to Hold Conference Call to Discuss Third Quarter 2010 Results
8. NeurogesX to Present at Oppenheimer & Co Healthcare Conference
9. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
10. NeurogesX Appoints Seasoned Sales and Marketing Executive as New Board Director
11. NeurogesX Receives FDA Approval of Qutenza(TM) (capsaicin) 8% Patch for Treatment of Postherpetic Neuralgia (PHN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... WAYNE, Pa. , July 31, 2015 /PRNewswire/ ... a fully integrated specialty pharmaceutical company focused on ... announced the closing of its previously announced underwritten ... stock at a public offering price of $11.25 ... the offering included 1,000,000 shares issued upon the ...
(Date:7/31/2015)... , July 31, 2015 ... for video, data and cloud computing operators has ... leading pharma giant for Internet of Things (IoT) ... applications offered on subscription model.      ... giant is striving for business innovations to make ...
(Date:7/30/2015)... (NYSE: RMD ) today announced results for its ... was $453.1 million, a 9 percent increase compared with ... increase on a constant currency basis).  Net income was ... 2014.  Diluted earnings per share for the quarter were ... The results for the quarter ended ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... SAN DIEGO, Oct. 18, 2011 Halozyme Therapeutics, ... company developing and commercializing products targeting the ... and drug delivery markets, today announced that the ... that women with HER2-positive early breast cancer who ...
... Oct. 17, 2011 Express Scripts (Nasdaq: ESRX ... North America, announced today its intention to release its third ... closes and will hold its quarterly conference call to discuss ... a.m. Eastern Time (8:30 a.m. Central Time). This ...
Cached Medicine Technology:Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial 2Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial 3Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial 4
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of the network ... their Healthy Home mission with the HOPE Movement of EvolvHealth. In what has been ... companies have agreed to join their missions of purpose together to change the course ...
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of ... making hers the very first small business donation to kick off the campaign for ... thirty years. Her legacy includes a complete line of raw, organic hair care products, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reputable source of authentic tickets ... Garden Arena. Fans of every genre of music will have an act they are ... day of the festival, the following artists will perform: Sam Smith, Coldplay, Kenny Chesney, ...
(Date:7/31/2015)... ... 31, 2015 , ... Ticket Down is a reliable source for authentic tickets ... Grant Park. The festival will end on Sunday, August 2nd. , ... annual Lollapalooza. This unique and unbelievably popular festival attracts the best in entertainment ...
(Date:7/31/2015)... Memphis, Tenn. (PRWEB) , ... July 31, 2015 , ... ... at Robert Church Park in Downtown Memphis on October 3, 2015. The Ride to ... partnership focused on cancer research between Methodist Healthcare, The West Clinic and The University ...
Breaking Medicine News(10 mins):Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:March4thforWellBeing Foundation Kickoff 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3
... a study testing a vaginal microbicide with an antiretroviral (ARV) ... was significantly more protective against HIV infection than a placebo ... the study, known as CAPRISA 004, are to be reported ... published online by the journal Science . ...
... N.C. Monday, July 19, 2010 Kidney disease ... a million individuals in the United States requiring dialysis ... The problem is particularly acute among African-Americans, whose rates ... of European Americans. As reported online this month ...
... Cancer researchers have discovered a previously unknown type ... cells that may lead to better insight about environmental ... in the journal Genome Research by researchers ... James Cancer Hospital and Richard J. Solove Research Institute ...
... sex offenders are often stereotyped and treated as socially ... they are more likely to be characterized by atypical ... coercive sex with peers and adults, and exposing their ... likely to have a history of sexual abuse themselves, ...
... HealthDay Reporter , MONDAY, July 19 (HealthDay ... illicit "club drug" Ecstasy may have one positive use: ... disorder (PTSD). The drug, also known by its ... standard treatments have failed. But experts stressed that ...
... July 2010 [Vienna, Austria]Scientists, practitioners and advocates from around ... leaders to commit at least $US20 billion to the ... its upcoming replenishment meeting in October. Because the level ... Global Fund,s grant levels for 2011-2013, the meeting is ...
Cached Medicine News:Health News:Microbicide trial results a turning point for HIV prevention, says team testing same gel 2Health News:Microbicide trial results a turning point for HIV prevention, says team testing same gel 3Health News:Investigators identify gene associated with kidney disease in African-American population 2Health News:Investigators identify gene associated with kidney disease in African-American population 3Health News:Breast cancer cells regulate multiple genes in response to estrogen-like compounds 2Health News:New study challenges stereotypes of adolescent sex offenders 2Health News:New study challenges stereotypes of adolescent sex offenders 3Health News:Researchers Use Ecstasy to Treat PTSD 2Health News:Researchers Use Ecstasy to Treat PTSD 3Health News:AIDS 2010 delegates and speakers unite in support of full funding for the Global Fund, the next milestone in drive for universal access 2Health News:AIDS 2010 delegates and speakers unite in support of full funding for the Global Fund, the next milestone in drive for universal access 3Health News:AIDS 2010 delegates and speakers unite in support of full funding for the Global Fund, the next milestone in drive for universal access 4
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
... product line has the right product for ... and from intubated patients to patients with ... both anesthesia and critical care applications., ... protection for patients and staff members. This ...
... Since 1991 Intersurgical Incorporated ... filters, heat and moisture ... therapy products, hand-held nebulizers ... of accessories and connectors ...
... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
Medicine Products: